Economic evidence in stroke: A review

[1] Sundberg G., Bagust A., Terent A., A model for costs of stroke services, Health Policy, 63, pp. 81-94, (2003)

[2] Stegmayr B., Asplund K., Stroke in Northern Sweden, Scand J Public Health Suppl, 61, pp. 60-69, (2003)

[3] Kaste M., Fogelholm R., Rissanen A., Economic burden of stroke and the evaluation of new therapies, Public Health, 112, pp. 103-112, (1998)

[4] Bradberry J.C., Fagan S.C., Gray D.R., Moon Y.S., New perspectives on the pharmacotherapy of ischemic stroke, J Am Pharm Assoc (Wash DC), 44, (2004)

[5] Sudlow C.L., Warlow C.P., Comparable studies of the incidence of stroke and its pathological types: Results from an international collaboration, Stroke, 28, pp. 491-499, (1997)

[6] Henriksson F., Fredrikson S., Masterman T., Jonsson B., Costs, quality of life and disease severity in multiple sclerosis: A cross-sectional study in Sweden, Eur J Neural, 8, pp. 27-35, (2001)

[7] Hodgson T.A., Meiners M.R., Cost-of-illness methodology: A guide to current practices and procedures, Milbank Mem Fund Q Health Soc, 60, pp. 429-462, (1982)

[8] Luce B.R., Elixhauser A., Estimating costs in the economic evaluation of medical technologies, Int J Technol Assess Health Care, 6, pp. 57-75, (1990)

[9] Payne K.A., Huybrechts K.F., Caro J.J., Craig Green T.J., Klittich W.S., Long term cost-of-illness in stroke: An international review, Pharmacoeconomics, 20, pp. 813-825, (2002)

[10] Porsdal V., Boysen G., Cost-of-illness studies of stroke, Cerebrovasc Dis, 7, pp. 258-263, (1997)

[1] Sundberg G., Bagust A., Terent A., A model for costs of stroke services, Health Policy, 63, pp. 81-94, (2003)

[2] Stegmayr B., Asplund K., Stroke in Northern Sweden, Scand J Public Health Suppl, 61, pp. 60-69, (2003)

[3] Kaste M., Fogelholm R., Rissanen A., Economic burden of stroke and the evaluation of new therapies, Public Health, 112, pp. 103-112, (1998)

[4] Bradberry J.C., Fagan S.C., Gray D.R., Moon Y.S., New perspectives on the pharmacotherapy of ischemic stroke, J Am Pharm Assoc (Wash DC), 44, (2004)

[5] Sudlow C.L., Warlow C.P., Comparable studies of the incidence of stroke and its pathological types: Results from an international collaboration, Stroke, 28, pp. 491-499, (1997)

[6] Henriksson F., Fredrikson S., Masterman T., Jonsson B., Costs, quality of life and disease severity in multiple sclerosis: A cross-sectional study in Sweden, Eur J Neural, 8, pp. 27-35, (2001)

[7] Hodgson T.A., Meiners M.R., Cost-of-illness methodology: A guide to current practices and procedures, Milbank Mem Fund Q Health Soc, 60, pp. 429-462, (1982)

[8] Luce B.R., Elixhauser A., Estimating costs in the economic evaluation of medical technologies, Int J Technol Assess Health Care, 6, pp. 57-75, (1990)

[9] Payne K.A., Huybrechts K.F., Caro J.J., Craig Green T.J., Klittich W.S., Long term cost-of-illness in stroke: An international review, Pharmacoeconomics, 20, pp. 813-825, (2002)

[10] Porsdal V., Boysen G., Cost-of-illness studies of stroke, Cerebrovasc Dis, 7, pp. 258-263, (1997)